公开(公告)号：WO2015143400A8

公开(公告)日：2017-01-05

申请号：PCT/US2015021871

申请日：2015-03-20

Applicant: PHARMACYCLICS LLC

Inventor： BYRD JOHN C ,  WOYACH JENNIFER A

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  A61K31/519 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/57426 ,  G01N2333/916 ,  G01N2800/52

Abstract: Described herein is a mutation that confers resistance to the treatment with a BTK inhibitor. Described herein is a modified PLCy2 polypeptide that is modified at amino acid position 742, 845, or 1140 and the modified PLCy2 polypeptide exhibits decreased inhibition (e.g., resistance) to a covalent and/or irreversible BTK inhibitor. Described herein are diagnostic methods for detecting the modified polypeptide and nucleic acid encoding the modified polypeptide and applications of the methods thereof. Described herein are compositions, combinations, and kits containing the modified polypeptide and methods of using the modified polypeptide. Also described herein are methods of using the modified polypeptide as screening agents for the identification and design of inhibitors of PLCy2.

Abstract translation: 本文描述了赋予对用BTK抑制剂治疗的抗性的突变。 本文描述的是在氨基酸位置742,845或1140修饰的修饰的PLCy2多肽，并且修饰的PLCy2多肽对共价和/或不可逆的BTK抑制剂表现出降低的抑制（例如抗性）。 本文描述了用于检测修饰的多肽和编码经修饰的多肽的核酸的诊断方法及其方法的应用。 本文描述的是含有修饰多肽的组合物，组合和试剂盒，以及使用修饰多肽的方法。 本文还描述了使用修饰的多肽作为用于鉴定和设计PLCy2的抑制剂的筛选剂的方法。

公开(公告)号：EP3119910A4

公开(公告)日：2018-02-21

申请号：EP15764524

申请日：2015-03-20

Applicant: PHARMACYCLICS LLC

Inventor： BYRD JOHN C ,  WOYACH JENNIFER A

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  A61K31/519 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/57426 ,  G01N2333/916 ,  G01N2800/52

Abstract: Described herein is a mutation that confers resistance to the treatment with a BTK inhibitor. Described herein is a modified PLCγ2 polypeptide that is modified at amino acid position 742, 845, or 1140 and the modified PLCγ2 polypeptide exhibits decreased inhibition (e.g., resistance) to a covalent and/or irreversible BTK inhibitor. Described herein are diagnostic methods for detecting the modified polypeptide and nucleic acid encoding the modified polypeptide and applications of the methods thereof. Described herein are compositions, combinations, and kits containing the modified polypeptide and methods of using the modified polypeptide. Also described herein are methods of using the modified polypeptide as screening agents for the identification and design of inhibitors of PLCγ2.

公开(公告)号：PH12021550052A1

公开(公告)日：2022-02-14

申请号：PH12021550052

申请日：2021-01-08

Applicant: PHARMACYCLICS LLC

Inventor： MIKLOS DAVID ,  BYRD JOHN C ,  DUBOVSKY JASON A ,  MUTHUSAMY NATARAJAN ,  JOHNSON AMY JO

IPC: A61K31/505 ,  A61K31/519 ,  A61P37/00

Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.

公开(公告)号：AU2020204270A1

公开(公告)日：2020-07-16

申请号：AU2020204270

申请日：2020-06-26

Applicant: PHARMACYCLICS LLC

Inventor： MIKLOS DAVID ,  BYRD JOHN C ,  DUBOVSKY JASON A ,  MUTHUSAMY NATARAJAN ,  JOHNSON AMY JO

IPC: A61K31/519 ,  A61K31/505 ,  A61P37/00

Abstract: METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASE Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.

公开(公告)号：AU2013337663A1

公开(公告)日：2015-06-11

申请号：AU2013337663

申请日：2013-11-01

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  MODY TARAK ,  LOVE RICHARD B ,  BYRD JOHN C ,  CHANG BETTY ,  DUBOVSKY JASON A ,  MUTHUSAMY NATARAJAN ,  JOHNSON AMY JO

IPC: A61K31/505 ,  A61K38/20 ,  A61P35/00

Abstract: Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

公开(公告)号：CA2928721A1

公开(公告)日：2015-04-30

申请号：CA2928721

申请日：2014-10-24

Applicant: PHARMACYCLICS LLC

Inventor： BYRD JOHN C ,  DUBOVSKY JASON A ,  MUTHUSAMY NATARAJAN ,  JOHNSON AMY JO ,  MIKLOS DAVID

IPC: A61K31/519 ,  A61K31/505 ,  A61P37/00

Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.

公开(公告)号：EP3060218A4

公开(公告)日：2017-07-19

申请号：EP14856623

申请日：2014-10-24

Applicant: PHARMACYCLICS LLC

Inventor： BYRD JOHN C ,  DUBOVSKY JASON A ,  MUTHUSAMY NATARAJAN ,  JOHNSON AMY JO ,  MIKLOS DAVID

IPC: A61K31/519 ,  A61K31/505 ,  A61P37/00

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61K31/56 ,  A61K35/17 ,  A61K35/28 ,  A61K38/13 ,  A61K45/06 ,  A61K2300/00

Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.

Abstract translation: 本文描述了使用ACK抑制剂治疗和预防移植物抗宿主病的方法。 所述方法包括向有需要的个体施用ACK抑制剂例如依鲁替尼用于治疗和预防移植物抗宿主疾病。

公开(公告)号：AR131751A2

公开(公告)日：2025-04-30

申请号：ARP240100237

申请日：2024-01-31

Applicant: PHARMACYCLICS LLC

Inventor： BYRD JOHN C ,  DUBOVSKY JASON A ,  MUTHUSAMY NATARAJAN ,  JOHNSON AMY JO ,  MIKLOS DAVID

IPC: A61K35/28 ,  A61K31/519 ,  A61K35/17 ,  A61K45/06

Abstract: Uso de inhibidores de ACK, tal como ibrutinib, en métodos terapéuticos y preventivos de la enfermedad de injerto versus huésped. Uso de un compuesto de fórmula (A) caracterizado porque es para prevenir la ocurrencia de enfermedad de injerto contra huésped (GVHD) o reducir la severidad de ocurrencia de GVHD en un paciente que requiere trasplante de células, en donde la fórmula (A) tiene la estructura mostrada a continuación.

公开(公告)号：MX385122B

公开(公告)日：2025-03-14

申请号：MX2016005294

申请日：2016-04-22

Applicant: PHARMACYCLICS LLC

Inventor： JOHNSON AMY JO ,  MIKLOS DAVID ,  DUBOVSKY JASON A ,  BYRD JOHN C ,  MUTHUSAMY NATARAJAN

IPC: A61K31/519 ,  A61K31/505 ,  A61P37/00

Abstract: Se describen en este documento métodos para tratar y prevenir la enfermedad de injerto contra huésped utilizando inhibidores de ACK. Los métodos incluyen administrar a un individuo en necesidad del mismo un inhibidor de ACK como ibrutinib para tratar y prevenir la enfermedad de injerto contra huésped.

公开(公告)号：AU2018233032A1

公开(公告)日：2018-10-11

申请号：AU2018233032

申请日：2018-09-21

Applicant: PHARMACYCLICS LLC

Inventor： BUGGY JOSEPH J ,  MODY TARAK ,  LOVE RICHARD B ,  BYRD JOHN C ,  CHANG BETTY ,  DUBOVSKY JASON A ,  MUTHUSAMY NATARAJAN ,  JOHNSON AMY JO

IPC: A61K31/505 ,  A61K38/20 ,  A61P35/00

Abstract: TEC FAMILY KINASE INHIBITOR ADJUV ANT THERAPY Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.